Poster presentations: Treatment 2022
11 Posters
Neurophysiological predictors of response to neurorehabilitation plus rTMS in MS
Young Investigator
Michelangelo Dini
62
Tolebrutinib Two-Year Safety and Efficacy in Relapsing Multiple Sclerosis Patients
Robert Fox
12
The efficacy of Natalizumab in Pediatric-Onset Multiple Sclerosis patients
Young Investigator
Marta Gaggiola
42
Alemtuzumab following natalizumab in pediatric- and adult-onset multiple sclerosis
Young Investigator
Marta Gaggiola
43
Evobrutinib acts on microglia: therapeutic implication in progression of MS?
Young Investigator
Anastasia Geladaris
19
Transcranial direct current stimulation applied in EAE mouse model
Winner Young Investigator Award
Young Investigator
Silvia Marenna
54
Best supportive care for PPMS prior to ocrelizumab: RETRO PPMS final results
Tanja Meier
49
Cladribine treatment in multiple sclerosis patients in Poland during COVID-19.
Young Investigator
Aleksandra Pogoda-Wesołowska
33
Evaluation of patient-reported outcomes: CLAWIR study 6-month interim analysis
Joachim Richter
27
MoOzaRt: Impact of ocrelizumab on patient-reported fatigue in RMS patients
Walter Siegenthaler
50
Physicians’ reason for DMT choice and unmet need in US patients with nonactive PPMS
Jonathan Willmer
23